- Stock: In Stock
Available Options
Description
HER2 ELISA Kit
Catalog Number: HER2-01-1154
Size: 1 plate (96 wells)
HER2 ELISA Kit is a sandwich enzyme-linked immunoassay for
the quantitative determination of HER2 with high sensitivity and specificity in
serum or plasma.
Kit
Performance
- Sensitivity: 10 pg/mL
- Assay Range: 10 – 1000 pg/mL
- Cross-reactivity: There is no
cross reaction with native immunoglobulins
- Recovery rate: 80 – 120% with
normal human serum or plasma samples with known concentrations.
- Precision
(CV
(%) = SD/mean X 100)
- Intra-Assay: CV < 20%
- Inter-Assay: CV < 20%
Materials
Supplied
List
of component
|
Components |
Quantity |
|
High binding Plate |
1 plate |
|
HER2 |
1 µg |
|
10x Capture |
700 µL |
|
10x Detection |
700 µL |
|
1x Streptavidin (HRP) (Avoid
light) |
12 mL |
|
1x Plate Coating Buffer |
15 mL |
|
1x Blocking Buffer |
15 mL |
|
2x Assay Diluent |
30 mL |
|
1x TMB Substrate (Avoid light) |
12 mL |
|
1x Stop Solution |
12 mL |
Storage
Instruction
The
components arrive with ice pack, and must immediately be stored at 2-8°C. The
kit components are stable at the date specified in CoA.
Supplementary
information
HER2
(Human Epidermal Growth Factor Receptor 2), also known as ERBB2, is a receptor
tyrosine kinase located on the cell membrane. Unlike most receptor tyrosine
kinases, HER2 does not have a known ligand and is naturally in a conformation
that readily forms dimers with other ERBB receptors.
When
HER2 forms homodimers or heterodimers—especially with HER3—it activates several
downstream signaling pathways that control cell proliferation and survival. The
most important pathways include the PI3K–AKT pathway, which promotes cell
survival and resistance to apoptosis, and the MAPK/ERK pathway, which
stimulates cell proliferation.
In
cancer, the ERBB2 gene becomes amplified, leading to overexpression of HER2
protein on the cell surface. HER2 amplification occurs in approximately 15–20%
of breast cancers and in a subset of gastric and esophageal cancers. Tumors
with HER2 overexpression often show more aggressive biological behavior but are
also highly responsive to targeted therapies.